Home > Publications database > Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment. > print

001     178465
005     20240229133807.0
024 7 _ |2 doi
|a 10.3390/cancers14010126
024 7 _ |2 pmid
|a pmid:35008290
037 _ _ |a DKFZ-2022-00091
041 _ _ |a English
082 _ _ |a 610
100 1 _ |0 0000-0001-8405-2219
|a Hill, Rebecca M
|b 0
245 _ _ |a Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment.
260 _ _ |a Basel
|b MDPI
|c 2021
336 7 _ |2 DRIVER
|a article
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
|b journal
|m journal
|s 1642065928_474
|x Review Article
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
336 7 _ |0 0
|2 EndNote
|a Journal Article
520 _ _ |a Relapsed medulloblastoma (rMB) accounts for a considerable, and disproportionate amount of childhood cancer deaths. Recent advances have gone someway to characterising disease biology at relapse including second malignancies that often cannot be distinguished from relapse on imaging alone. Furthermore, there are now multiple international early-phase trials exploring drug-target matches across a range of high-risk/relapsed paediatric tumours. Despite these advances, treatment at relapse in pre-irradiated patients is typically non-curative and focuses on providing life-prolonging and symptom-modifying care that is tailored to the needs and wishes of the individual and their family. Here, we describe the current understanding of prognostic factors at disease relapse such as principal molecular group, adverse molecular biology, and timing of relapse. We provide an overview of the clinical diagnostic process including signs and symptoms, staging investigations, and molecular pathology, followed by a summary of treatment modalities and considerations. Finally, we summarise future directions to progress understanding of treatment resistance and the biological mechanisms underpinning early therapy-refractory and relapsed disease. These initiatives include development of comprehensive and collaborative molecular profiling approaches at relapse, liquid biopsies such as cerebrospinal fluid (CSF) as a biomarker of minimal residual disease (MRD), modelling strategies, and the use of primary tumour material for real-time drug screening approaches.
536 _ _ |0 G:(DE-HGF)POF4-312
|a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |2 Other
|a medulloblastoma
650 _ 7 |2 Other
|a relapse
700 1 _ |a Plasschaert, Sabine L A
|b 1
700 1 _ |a Timmermann, Beate
|b 2
700 1 _ |0 0000-0001-5993-8077
|a Dufour, Christelle
|b 3
700 1 _ |a Aquilina, Kristian
|b 4
700 1 _ |a Avula, Shivaram
|b 5
700 1 _ |a Donovan, Laura
|b 6
700 1 _ |0 0000-0001-7488-1734
|a Lequin, Maarten
|b 7
700 1 _ |a Pietsch, Torsten
|b 8
700 1 _ |a Thomale, Ulrich
|b 9
700 1 _ |a Tippelt, Stephan
|b 10
700 1 _ |a Wesseling, Pieter
|b 11
700 1 _ |a Rutkowski, Stefan
|b 12
700 1 _ |a Clifford, Steven C
|b 13
700 1 _ |0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|a Pfister, Stefan M
|b 14
|u dkfz
700 1 _ |0 0000-0003-4763-4329
|a Bailey, Simon
|b 15
700 1 _ |0 0000-0001-5714-007X
|a Fleischhack, Gudrun
|b 16
773 _ _ |0 PERI:(DE-600)2527080-1
|a 10.3390/cancers14010126
|g Vol. 14, no. 1, p. 126 -
|n 1
|p 126
|t Cancers
|v 14
|x 2072-6694
|y 2021
909 C O |o oai:inrepo02.dkfz.de:178465
|p VDB
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|a Deutsches Krebsforschungszentrum
|b 14
|k DKFZ
913 1 _ |0 G:(DE-HGF)POF4-312
|1 G:(DE-HGF)POF4-310
|2 G:(DE-HGF)POF4-300
|3 G:(DE-HGF)POF4
|4 G:(DE-HGF)POF
|a DE-HGF
|b Gesundheit
|l Krebsforschung
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2021
915 _ _ |0 StatID:(DE-HGF)0100
|2 StatID
|a JCR
|b CANCERS : 2019
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0200
|2 StatID
|a DBCoverage
|b SCOPUS
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0300
|2 StatID
|a DBCoverage
|b Medline
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0320
|2 StatID
|a DBCoverage
|b PubMed Central
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0501
|2 StatID
|a DBCoverage
|b DOAJ Seal
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0500
|2 StatID
|a DBCoverage
|b DOAJ
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0030
|2 StatID
|a Peer Review
|b DOAJ : Blind peer review
|d 2021-05-04
915 _ _ |0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|a Creative Commons Attribution CC BY (No Version)
|b DOAJ
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0600
|2 StatID
|a DBCoverage
|b Ebsco Academic Search
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0030
|2 StatID
|a Peer Review
|b ASC
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0199
|2 StatID
|a DBCoverage
|b Clarivate Analytics Master Journal List
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0160
|2 StatID
|a DBCoverage
|b Essential Science Indicators
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)1050
|2 StatID
|a DBCoverage
|b BIOSIS Previews
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)1190
|2 StatID
|a DBCoverage
|b Biological Abstracts
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0113
|2 StatID
|a WoS
|b Science Citation Index Expanded
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0150
|2 StatID
|a DBCoverage
|b Web of Science Core Collection
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)9905
|2 StatID
|a IF >= 5
|b CANCERS : 2019
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0561
|2 StatID
|a Article Processing Charges
|d 2021-05-04
915 _ _ |0 StatID:(DE-HGF)0700
|2 StatID
|a Fees
|d 2021-05-04
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21